Functional Dyspepsia

Definition and Epidemiology

• Postprandial distress syndrome (PDS) - bothersome postprandial fullness and/or early satiation, at least 3 days/week. Accounts for roughly two-thirds of FD patients.
• Epigastric pain syndrome (EPS) - bothersome epigastric pain or burning, at least 1 day/week, which may occur with meals, be relieved by meals, or occur while fasting. Accounts for around 15%, with the remainder having overlapping PDS/EPS features.

Pathophysiology

• Delayed or, less commonly, rapid gastric emptying (delayed emptying in about 30% of patients, though symptom correlation is weak except for severe nausea)
• Impaired gastric accommodation to a meal
• Visceral hypersensitivity - heightened perception of gastric/duodenal distention and acid exposure
• Low-grade duodenal inflammation/eosinophilia, increased mucosal permeability, and reactivity to food antigens
• H. pylori gastritis (if eradication resolves symptoms, the patient is reclassified as having H. pylori-associated dyspepsia rather than true FD)
• Psychosocial factors (anxiety, somatization) and altered brain-gut signaling
• Goldman-Cecil Medicine, p. 1421-1422; Sleisenger and Fordtran's Gastrointestinal and Liver Disease, p. 206.

Diagnosis

Treatment

Recent Evidence (supplementing the textbook material)

• Exercise therapy showed benefit for FD symptoms and quality of life in a 2025 systematic review/meta-analysis (PMID: 40619318).
• Psychotherapeutic approaches (CBT, hypnosis, mindfulness) improved FD symptoms and associated anxiety/depression in a 2024 meta-analysis (PMID: 39210762).
• Acupuncture showed benefit over sham/control in a 2024 Bayesian network meta-analysis (PMID: 38761869).
• STW-5-II (an herbal preparation) showed efficacy and safety in a patient-level meta-analysis (PMID: 38246134).
• A 2025 network meta-analysis suggested some Chinese patent medicines combined with conventional therapy may outperform conventional therapy alone (PMID: 41458491).

Exercise Therapy for Functional Dyspepsia

The evidence base

• All 15 trials reported symptom improvement with exercise therapy; 9 assessed "effective rate" and 4 evaluated overall symptom scores.
• Core dyspeptic symptoms improved, particularly epigastric fullness and pain.
• Exercise also improved quality of life (6 studies), sleep quality (2 studies), and reduced depression (2 studies).
• Exercise was associated with changes in gut hormone levels - motilin (MTL), gastrin (GAS), and vasoactive intestinal peptide (VIP) - though not consistently across all studies, suggesting a hormonal/motility-mediated mechanism.
• No serious adverse events were reported across any trial.

Supporting individual trial

• Glasgow Dyspepsia Severity Score (GDSS)
• Depression Anxiety Stress Scales (DASS-42)
• Visual analogue scale (VAS) for symptom severity

Proposed mechanisms

• Modest acceleration of gastric emptying and whole-gut transit - relevant since roughly 30% of FD patients have delayed gastric emptying (per the pathophysiology of FD).
• Improved gastric accommodation to a meal, which is impaired in many FD patients.
• Attenuation of stress-related symptom amplification via autonomic nervous system effects (reduced sympathetic drive, improved vagal tone) - plausible given FD's link to visceral hypersensitivity and gut-brain interaction.
• Epidemiologic data support this directionality: population studies (Koloski et al. 2020; Furukawa et al. 2022) found FD is independently associated with lower baseline exercise levels, and sedentary behavior itself may worsen symptoms by slowing gastrointestinal peristalsis.

Practical takeaway

• Trial quality is still limited (small sample sizes, heterogeneous protocols, risk-of-bias concerns).
• No trial has shown exercise alone outperforms standard care head-to-head; benefit is best documented when exercise is added to conventional treatment.

Exercise Types Used in Functional Dyspepsia (FD) Trials

1. Moderate aerobic exercise

• Protocol: Moderate aerobic exercise, 30 minutes/session, 5 times/week, for 6 weeks, added on top of conventional treatment (PPI-based).
• Outcome: Significantly better improvement in Glasgow Dyspepsia Severity Score, anxiety/depression/stress scores (DASS-42), and VAS symptom scores versus conventional treatment alone.
• Type of aerobic activity wasn't restricted to one modality (typically brisk walking/jogging/cycling-type activity in these protocols), but the trial itself just specifies "moderate aerobic exercise."

2. Aerobic exercise + Benson's Relaxation Therapy (combined)

• Protocol: Aerobic exercise (5 sessions/week) combined with Benson's Relaxation Therapy - 40 minutes/day, consisting of diaphragmatic breathing and progressive muscle relaxation, applied 20 minutes morning and 20 minutes evening, for 8 weeks. Control group received Benson's relaxation alone.
• Outcome: The exercise + relaxation group showed greater improvement in dyspepsia severity, cortisol, sleep quality, and estradiol levels than relaxation alone.

3. Breathing exercises with vagal biofeedback

• Protocol: Slow, controlled breathing at 6 breaths/minute, 5 minutes daily for 4 weeks, using vagal biofeedback software (targeting respiratory sinus arrhythmia).
• Outcome: Improved drinking capacity (proxy for gastric accommodation) and dyspepsia-related quality of life, though it did not change baseline vagal tone.
• Mechanistic rationale: many FD patients have impaired gastric accommodation linked to low vagal tone; slow breathing aims to boost parasympathetic/vagal activity.

4. Yoga

• Status: theoretical/limited evidence, not yet a completed dedicated RCT in adult FD. A 2023 narrative review (Setia et al., PMID: 38147600) found that, apart from one pediatric trial on functional abdominal pain disorders that included a small subset (11.6%) of FD cases, no dedicated yoga RCT exists in adults with FD. The review is theoretical, discussing plausible mechanisms (improved gastric motility, fundic accommodation, reduced hypersensitivity, reduced psychological distress) rather than reporting trial results. A separate case series (PMID: 37216873) by the same group reported symptom benefit with adjuvant yoga, but this is uncontrolled, low-quality evidence.

Summary table

Omeprazole + Albendazole

Omeprazole (capsules)

• Class: Proton pump inhibitor (PPI)
• Mechanism: Irreversibly inhibits the H+/K+-ATPase ("proton pump") in gastric parietal cells, suppressing acid secretion
• Uses: GERD, gastric/duodenal ulcers, erosive esophagitis, dyspepsia, Zollinger-Ellison syndrome, and as part of H. pylori eradication regimens (with antibiotics)
• Formulation note: Delayed-release capsules - the enteric coating protects the drug from being destroyed by stomach acid before absorption. Best taken 30-60 minutes before a meal (usually breakfast).

Albendazole

• Class: Benzimidazole anthelmintic
• Mechanism: Binds selectively to parasite β-tubulin, inhibiting microtubule polymerization; also inhibits mitochondrial fumarate reductase and glucose uptake in helminths, effectively starving and paralyzing the worm - Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 1345; Sleisenger and Fordtran's Gastrointestinal and Liver Disease, p. 692.
• Uses: Soil-transmitted helminths (roundworm, hookworm, whipworm), neurocysticercosis, hydatid disease (echinococcosis), cutaneous/visceral larva migrans
• Absorption: Poorly and erratically absorbed on its own; absorption is significantly enhanced by co-administration with a fatty meal - Katzung's Basic and Clinical Pharmacology, p. 3103; Goodman & Gilman's, p. 2093. It undergoes rapid first-pass hepatic metabolism to its active metabolite, albendazole sulfoxide.

Is there an interaction or an approved combination?

• No fixed-dose combination product of omeprazole + albendazole was found in the authoritative pharmacology texts or current drug databases. This differs from combinations like albendazole + ivermectin, which are established antiparasitic co-formulations (e.g., for soil-transmitted helminths and lymphatic filariasis).
• No clinically significant pharmacokinetic interaction between omeprazole and albendazole is documented in the major pharmacology/GI references I checked. Albendazole's poor bioavailability is driven mainly by low aqueous solubility and first-pass hepatic metabolism, not by gastric pH-dependent dissolution (unlike some azole antifungals, e.g., ketoconazole, which do need an acidic stomach for dissolution and are meaningfully impaired by PPIs). So omeprazole raising gastric pH is not expected to meaningfully blunt albendazole absorption.
• Practical co-administration tip: since albendazole absorption is boosted by fatty food, it's reasonable to take albendazole with a meal (ideally one containing some fat), while omeprazole is taken before a meal on an empty stomach for optimal acid suppression. They don't need to be separated by a specific time interval for interaction avoidance - the timing difference is just to optimize each drug's own absorption/efficacy, not because of a drug-drug interaction.